| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1816714 |
| P698 | PubMed publication ID | 30779529 |
| P50 | author | Cezary Szczylik | Q9188497 |
| P2093 | author name string | Igor Bondarenko | |
| Robert Hawkins | |||
| Elizabeth R Plimack | |||
| Michael B Atkins | |||
| Mei Chen | |||
| Brian I Rini | |||
| Frédéric Pouliot | |||
| Jens Bedke | |||
| Satoshi Tamada | |||
| Bohuslav Melichar | |||
| Ihor Vynnychenko | |||
| Sophie Tartas | |||
| Qiong Shou | |||
| Thomas Powles | |||
| Denis Soulières | |||
| Yen-Hwa Chang | |||
| Delphine Borchiellini | |||
| Dmitry Nosov | |||
| Sergio J Azevedo | |||
| Boris Alekseev | |||
| Rodolfo F Perini | |||
| Maurice Markus | |||
| Viktor Stus | |||
| Rustem Gafanov | |||
| Anna Kryzhanivska | |||
| KEYNOTE-426 Investigators | |||
| Raymond S McDermott | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pembrolizumab | Q13896859 |
| P304 | page(s) | 1116-1127 | |
| P577 | publication date | 2019-02-16 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | |
| P478 | volume | 380 |
| Q89849302 | A Case Report with Severe Thrombocytopenia Induced by Axitinib |
| Q89647005 | A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma |
| Q91272659 | A view on drug resistance in cancer |
| Q96131947 | Advanced renal cell carcinoma and COVID-19 - a personal perspective |
| Q95841180 | Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial |
| Q90630067 | Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial |
| Q98243078 | Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer |
| Q99207826 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial |
| Q96685963 | Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events |
| Q92128636 | Axitinib-ICIs boost the RCC armamentarium |
| Q97067578 | BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer |
| Q92541901 | Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer |
| Q90070600 | C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab |
| Q92533805 | Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial |
| Q89520843 | Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma? |
| Q89532702 | Checkpoint inhibitor immunotherapy in kidney cancer |
| Q94564064 | Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer |
| Q92098290 | Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma |
| Q89602407 | Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis |
| Q94487404 | Clinical implications of food-drug interactions with small-molecule kinase inhibitors |
| Q92354261 | Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC |
| Q99350243 | Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity |
| Q92219253 | Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer |
| Q90074156 | Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents |
| Q90116668 | Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma |
| Q89517466 | Combining microenvironment normalization strategies to improve cancer immunotherapy |
| Q98289189 | Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis |
| Q98286782 | Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials |
| Q91912664 | Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma |
| Q97527459 | Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis |
| Q104289186 | Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q89669601 | Current State of Systemic Therapies for Advanced Renal Cell Carcinoma |
| Q96811984 | Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors |
| Q91695000 | Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway |
| Q91910929 | Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma |
| Q97642105 | Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events |
| Q98510144 | Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma |
| Q91958132 | Durable complete response in renal cell carcinoma clinical trials |
| Q64902254 | Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. |
| Q90999199 | Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma |
| Q89590901 | Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population |
| Q91986120 | Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis |
| Q93104008 | Emerging therapeutic agents for genitourinary cancers |
| Q92340667 | Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance |
| Q91623695 | Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? |
| Q104105690 | Enhancing anti-tumour efficacy with immunotherapy combinations |
| Q96811961 | Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma |
| Q90948664 | Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival |
| Q92480854 | Evolution in upfront treatment strategies for metastatic RCC |
| Q96811951 | Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma |
| Q92811990 | Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma |
| Q98629630 | Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence after Nephrectomy for Renal Cell Carcinoma |
| Q90600541 | First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options |
| Q98189587 | First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours |
| Q102152250 | First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology |
| Q98892921 | First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis |
| Q100426629 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm |
| Q90416214 | Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives |
| Q96610153 | Genomic profiling in renal cell carcinoma |
| Q89931203 | Glucocorticoids and immune checkpoint inhibitors in glioblastoma |
| Q96158994 | Gross Hematuria Eight Years Following Nephrectomy for Renal Cell Cancer |
| Q90590637 | Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers |
| Q91152047 | Health technology assessment methodology in metastatic renal cell carcinoma |
| Q95322793 | Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma |
| Q91626168 | Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma |
| Q90044993 | Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma |
| Q98216339 | Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research |
| Q94526293 | Immune checkpoint inhibitors in genitourinary malignancies |
| Q90257606 | Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy |
| Q93138987 | Immune-based combination therapy for metastatic kidney cancer |
| Q94550478 | Immune-related adverse events of checkpoint inhibitors |
| Q90650604 | Immuno-oncology gene expression profiling of FFPE clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing |
| Q89521181 | Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma |
| Q100425524 | Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options |
| Q91609282 | Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database |
| Q89602909 | Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges |
| Q92535665 | Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies |
| Q92707213 | Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study |
| Q109715902 | Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC) |
| Q99614963 | Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment |
| Q96023037 | Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma |
| Q100425500 | Kidney Cancer: An Overview of Current Therapeutic Approaches |
| Q90220303 | Lactate dehydrogenase: a marker of diminished antitumor immunity |
| Q89647095 | Lenvatinib in Management of Solid Tumors |
| Q64099156 | Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report |
| Q90651821 | Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019 |
| Q90000428 | Management of metastatic renal cell carcinoma: The complexity of choice |
| Q98465720 | Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade |
| Q96811975 | Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma |
| Q99630947 | Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma |
| Q89860576 | New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies |
| Q91642003 | New emerging targets in cancer immunotherapy: the role of TIM3 |
| Q90609011 | Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine |
| Q92707207 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial |
| Q90257496 | Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors |
| Q96132776 | Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab |
| Q92746800 | Optimising first-line treatment for metastatic renal cell carcinoma |
| Q96222585 | Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy |
| Q89682905 | Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis |
| Q94483817 | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| Q96303222 | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake |
| Q92350780 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN |
| Q92061895 | Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma |
| Q98945511 | Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date |
| Q89507041 | Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100 |
| Q104104257 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial |
| Q91792229 | Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer |
| Q92801272 | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors |
| Q89875243 | Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003 |
| Q92733969 | Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection |
| Q90737500 | Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors |
| Q99605164 | Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma |
| Q99237659 | Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer |
| Q92176242 | Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma |
| Q98771169 | Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma |
| Q91998697 | Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma |
| Q99628992 | Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era |
| Q90745708 | Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade |
| Q99406560 | Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients |
| Q91851580 | Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial |
| Q91851573 | Ramucirumab plus pembrolizumab: can we make the maths work? |
| Q92442591 | Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors |
| Q90319417 | Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma |
| Q90665021 | Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer? |
| Q92707201 | Renal cell carcinoma treatment after first-line combinations |
| Q92109812 | Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies |
| Q98291421 | Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs |
| Q92815283 | Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor |
| Q97520423 | Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies |
| Q94476096 | Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report |
| Q92713278 | Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? |
| Q102214595 | Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies |
| Q90428396 | Revisiting the role of lymph node dissection in renal cell carcinoma |
| Q92793810 | Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis |
| Q89521071 | Role of immunotherapy in metastatic renal cell cancer: past, present and future |
| Q90428468 | Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches" |
| Q90690141 | Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study |
| Q89747242 | Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma |
| Q92444430 | Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities |
| Q100533974 | Sarcomatoid renal cell carcinoma: biology, natural history and management |
| Q96811967 | Sequencing Therapies for Metastatic Renal Cell Carcinoma |
| Q91765164 | Sequencing therapy for advanced renal cancer |
| Q89520832 | Sequential treatment of metastatic renal cancer in a complex evolving landscape |
| Q92707219 | Should we use combination therapy for all advanced renal cell carcinoma? |
| Q91844057 | Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data |
| Q97527450 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial |
| Q91995955 | Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer |
| Q98771256 | Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality |
| Q92737319 | Systemic therapy for chromophobe renal cell carcinoma: A systematic review |
| Q101136379 | TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q64253749 | Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" |
| Q98946916 | Targeting angiogenesis for liver cancer: Past, present, and future |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q64076626 | Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma |
| Q64968881 | Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy. |
| Q92826118 | The Changing Therapeutic Landscape of Metastatic Renal Cancer |
| Q93078876 | The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice |
| Q90310543 | The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy |
| Q96811993 | The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma |
| Q92631829 | The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma |
| Q91809322 | The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment |
| Q93048945 | The PD-1/PD-L1 pathway in advanced prostate cancer-have we milked this cow? |
| Q92058683 | The Role of Immunotherapy in Urologic Cancers |
| Q95936578 | The future of cancer immunotherapy: microenvironment-targeting combinations |
| Q98177248 | The immunology of renal cell carcinoma |
| Q96639063 | The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort |
| Q95261759 | The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer-a case report |
| Q90911537 | The pro-tumorigenic host response to cancer therapies |
| Q89520966 | The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases |
| Q92128972 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) |
| Q91994863 | Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma |
| Q64962223 | Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. |
| Q91765160 | Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study |
| Q93139113 | Towards individualized therapy for metastatic renal cell carcinoma |
| Q99411638 | Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade |
| Q90131626 | Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma |
| Q91817083 | Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma |
| Q90671025 | Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma |
| Q92855987 | Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope? |
| Q90160018 | Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma |
| Q104517656 | [French ccAFU guidelines - update 2020-2022: management of kidney cancer] |
| Q97067536 | [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer] |
| Q89475892 | [Risk-adapted therapy for metastatic renal cell carcinoma] |
Search more.